Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA

TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC). To accelerate the development of this ne... Biopharmaceuticals, Oncology, FDA Senhwa Biosciences, Silmitasertib, basal cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news